Belly fat melting shot? phase 3 trial begins.
NCT ID NCT07140939
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether an injection called CBL-514 can safely reduce abdominal fat. 300 adults with moderate to severe belly fat will receive either the drug or a placebo. The study measures fat loss by MRI and patient ratings over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CBL-514 injection
- What this could lead to
- If it works, this could offer a non-surgical way to reduce stubborn belly fat.
- What could go wrong
- This is an early Phase 3 trial, so results are not yet known. The treatment may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBCUTANEOUS FAT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site 1
Encinitas, California, 92024, United States
-
Investigational site 10
Nashville, Tennessee, 37215, United States
-
Investigational site 11
Pflugerville, Texas, 78660, United States
-
Investigational site 12
Vancouver, British Columbia, V5Z1H4, Canada
-
Investigational site 13
Toronto, Ontario, M4W2N4, Canada
-
Investigational site 2
West Palm Beach, Florida, 33401, United States
-
Investigational site 3
Chicago, Illinois, 60610, United States
-
Investigational site 4
Baton Rouge, Louisiana, 70809, United States
-
Investigational site 5
Hunt Valley, Maryland, 21030, United States
-
Investigational site 6
Omaha, Nebraska, 68144, United States
-
Investigational site 7
Hackensack, New Jersey, 07601, United States
-
Investigational site 8
New York, New York, 10028, United States
-
Investigational site 9
Charlotte, North Carolina, 28207, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.